Articles related to GENE THERAPY

Healthcare professionals are navigating a complex dialogue on COVID-19 vaccine shedding, underscored by FDA acknowledgments and Pfizer protocols that hint at the nuanced risks of gene therapy product exposure.

The comparative modeling analysis of gene therapy for sickle cell disease underscores its potential cost-effectiveness and value in enhancing patient quality of life. With estimated ICERs significantly varying under different perspectives, the findings advocate for a nuanced approach to assessing novel therapies within the broader healthcare landscape.

Roctavian represents a turning point in hemophilia A management, offering patients like Maxwell a potential lifetime of relief from traditional therapies. This gene therapy directly targets the genetic cause, paving the way for innovative treatments in genetic disorders.

The therapy aims to restore progranulin protein levels in the brain, marking a significant step forward in the treatment of neurodegenerative disorders.

Learn how CRISPR-Cas9 gene editing holds the promise of elevating fetal hemoglobin levels and significantly reducing sickle cell disease manifestations. Explore the study’s findings to consider this potential game-changer for your practice.

This phase 1–2 study of gene therapy in Crigler–Najjar syndrome patients offers promising insights into a novel treatment approach. Explore the detailed findings to understand how this therapy could revolutionize the management of this rare and severe condition.